ProCE Banner Activity

IMPAACT 2017/MOCHA Cohort 2: Wk 24 Safety, Efficacy, and PK Data After Switching to LA CAB + RPV in Adolescents Living With HIV

Conference Coverage

In a phase I/II study of adolescents living with HIV in the United States, Uganda, Botswana, South Africa, and Thailand, switching from oral ART to LA CAB + RPV was safe and maintained viral suppression at Week 24. 

Released: March 08, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare